179003-08-8

Basic information

• Product Name: Methyl 3-(1-piperazinyl)benzoate
• Synonyms: Methyl 3-(1-piperazinyl)benzoate;Benzoic acid, 3-(1-piperazinyl)-, Methyl ester;METHYL 3-(PIPERAZIN-1-YL)BENZOATE;methyl3-(piperazin-1-yl)benzoatehydrochloride(WX160441)
• CAS NO: 179003-08-8
• Molecular Formula: C₁₂H₁₆N₂O₂
• Molecular Weight: 220.27
• Mol File: 179003-08-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 377.046 °C at 760 mmHg
• Flash Point: 181.831 °C
• Appearance: /
• Density: 1126 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• PKA: 8.85±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-(1-piperazinyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(1-piperazinyl)benzoate(179003-08-8)
• EPA Substance Registry System: Methyl 3-(1-piperazinyl)benzoate(179003-08-8)

Safety Data

• Hazardous Substances Data: 179003-08-8(Hazardous Substances Data)

Usage

General Description

Methyl 3-(1-piperazinyl)benzoate is a chemical compound with the molecular formula C14H18N2O2. It is a piperazine derivative, containing a benzene ring with a methyl ester group and a piperazine ring attached. Methyl 3-(1-piperazinyl)benzoate is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and active pharmaceutical ingredients. It has been reported to possess anticancer, anticonvulsant, and antihyperglycemic properties in preclinical studies. Additionally, it has been investigated for its potential as a central nervous system depressant and anxiolytic drug. Methyl 3-(1-piperazinyl)benzoate is also utilized as a research chemical in the development of new therapeutic agents. Overall, this compound plays a crucial role in drug discovery and development due to its diverse pharmacological activities and potential therapeutic applications.

InChI:InChI=1/C12H16N2O2/c1-16-12(15)10-3-2-4-11(9-10)14-7-5-13-6-8-14/h2-4,9,13H,5-8H2,1H3

Upstream product

• 4518-10-9 Methyl 3-aminobenzoate 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 67-56-1 methanol 
• 446831-28-3 3-(piperazin-1-yl)benzoic acid 
• 618-89-3 methyl 3-bromobenzoate 
• 179003-10-2 tert-butyl 4-(3-(methoxycarbonyl)phenyl)-piperazine-1-carboxylate 

Downstream Products

• 179003-10-2 tert-butyl 4-(3-(methoxycarbonyl)phenyl)-piperazine-1-carboxylate 
• 1447332-02-6 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid 
• 1447332-14-0 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid 
• 1447330-37-1 3-[1-oxo-6-(3-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]propionic acid trifluoroacetate 
• 1447330-50-8 3-[1-oxo-6-(3-piperazinium-4-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]butyric acid chloride 
• 193818-13-2 4-(3-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1447331-52-3 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid methyl ester 
• 1447331-70-5 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl ester 

Relevant articles and documents

Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th

Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tiss

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.